BTIG analyst Jeet Mukherjee assumed coverage of ArriVent Biopharma (AVBP) with a Buy rating and $42 price target The firm says its Bay call is anchored by the FURVENT phase 3 readout that is now tracking to mid-2026 and ALPACCA phase 3 in first-line PACC – P-loop and alphaC-helix compressing – which dosed its first patient in December of 2025, the analyst tells investors in a research note. BTIG believes that the stock materially discounts a successful FURVENT outcome.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
- ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
- ArriVent Biopharma price target raised to $33 from $31 at Citi
- Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
- ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential